Clinical Edge Journal Scan

Laparoscopic gastrectomy for gastric cancer: Postoperative NSAID use requires caution


 

Key clinical point: Postoperative nonsteroidal anti-inflammatory drug (NSAID) use in intravenous patient-controlled analgesia (IV-PCA) is associated with an increased risk for anastomotic leakage, duodenal stump leakage, intra-abdominal bleeding, and intra-abdominal inflammation in patients who undergo laparoscopic gastrectomy for gastric cancer.

Major finding: The NSAID vs non-NSAID group had a significantly higher incidence rate of anastomotic leakage (2.4% vs 0.7%; P = .002), duodenal stump leakage (1.8% vs 0.6%; P = .007), intra-abdominal bleeding (2.1% vs 0.7%; P = .005), and intra-abdominal abscess (1.5% vs 0.4%; P = .008).

Study details: This single-center retrospective study included 2150 patients with gastric cancer who underwent went laparoscopic gastrectomy and thereafter did (n = 935) or did not (n = 1,215) receive NSAID in IV-PCA.

Disclosures: This study was sponsored by the Korean Gastric Cancer Association. The authors declared no conflicts of interest.

Source: Kim SJ et al. Impact of postoperative NSAIDs (IV-PCA) use on short-term outcomes after laparoscopic gastrectomy for the patients of gastric cancer. Surg Endosc. 2022 (Sep 21). Doi: 10.1007/s00464-022-09600-4

Recommended Reading

Longer interval between bevacizumab exposure and CRC surgery could prevent additional mortality risk
MDedge Hematology and Oncology
FDA approves new immunotherapy combo for liver cancer
MDedge Hematology and Oncology
Pancreatic cancer screening appears safe, effective for high-risk patients
MDedge Hematology and Oncology
EUS-guided RF ablation doubles survival for unresectable pancreatic cancer
MDedge Hematology and Oncology
Some young CRC patients are missing out on genetic counseling, testing
MDedge Hematology and Oncology
Paclitaxel + carboplatin + capecitabine regimen shows promise in advanced gastric cancer
MDedge Hematology and Oncology
Robotic-assisted distal gastrectomy: A feasible treatment option for advanced gastric cancer
MDedge Hematology and Oncology
Multimodal treatment of gastric cancer affects outcomes in a stage‐specific manner
MDedge Hematology and Oncology
Gastric cancer: Neoadjuvant treatment status should not guide the extent of lymphadenectomy
MDedge Hematology and Oncology
Early gastric cancer: Bleeding risk after ESD similar between patients with surgically altered and whole stomach
MDedge Hematology and Oncology